Search Results

ductal carcinoma who has triple-negative disease and no BRCA1 or BRCA2 mutation identified would be an anthracycline and taxane-based regimen, such as the regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel

trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model . Clin Cancer Res 2005 ; 11 ( 19 Pt 1 ): 6966 – 6971 . 30. Eleutherakis-Papaiakovou V Bamias A Dimopoulos MA

. Kelsey CR Chino JP Willett CG . Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer . Int J Radiat Oncol Biol Phys 2007 ; 69 : 770 – 776 . 12. Javeri H Arora R Correa AM . Influence of induction

-stage disease settings. After its initial FDA approval in 1998 for first-line treatment of HER2-positive metastatic breast cancer in combination with paclitaxel, a series of pivotal adjuvant studies documented statistically significant improvements in both

FOLFIRINOX [5-FU, leucovorin, irinotecan, and oxaliplatin] or gemcitabine) and the APACT study (NCT01964430; surgery followed by either gemcitabine/nanoparticle albumin-bound [nab]-paclitaxel or gemcitabine monotherapy). Turning to neoadjuvant therapy, Dr

(Asia=71.1%; West=89.0%). The five most common 1L treatment regimens were cisplatin + 5-FU (27.4%), carboplatin + paclitaxel (8.4%), FOLFOX (8.0%), 5-FU (+leucovorin) (6.6%), and carboplatin + 5-FU (5.9%), although differences were observed by geography

recommended a patient-specific treatment plan that was not part of NCCN. Specific substitutions such as Capecitabine for 5-FU, Carboplatin for Cisplatin, and Paclitaxel for Docetaxel that were not part of NCCN were made to for patient tolerance of therapy

chemotherapy as per Keynote-407 (pembrolizumab, carboplatin and paclitaxel) due to continuous effusions, followed by protocol Keynote-189 (pembrolizumab, cisplatin, pemetrexed). Once his molecular testing revealed an EML4-ALK fusion, he was switched to oral

to single-agent platinum therapy. 111 , 112 Cisplatin-based combination chemotherapy regimens, such as cisplatin/paclitaxel and cisplatin/topotecan, have been extensively investigated in clinical studies. 111 , 112 , 114 – 116 A randomized phase

study evaluating carboplatin and 1 of 2 paclitaxel formulations in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) and a marginal PS found a significant difference in OS based on the geographic location of the patients. 8